Protocol Ledger

NCT06122649 · Phase III · COMPLETED

A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)

Interventional Phase III clinical trial protocol NCT06122649 sponsored by Amgen in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-11-27 Enrollment: 203 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06122649
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)203 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06122649
Protocol FieldVerified Registry Value
NCT IdentifierNCT06122649
Consolidated Lead SponsorAmgen
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment203 participants (ACTUAL)
Registered Start Date2023-11-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI